NDA 219019 · Genzyme Corp
Qfitlia
Fitusiran Sodium · Subcutaneous · Antithrombin-directed RNA Interaction; Small Interfering RNA
NovelOrphanCDER novel approval, Mar 28, 2025: To prevent or reduce the frequency of bleeding episodes in hemophilia A or B
Last checked: Nov 19, 2026Latest source record: Mar 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Mar 28, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
7 Phase 3, 2 recruiting
FAERS reports
56
23 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: THROMBOTIC EVENTS AND ACUTE AND RECURRENT GALLBLADDER DISEASE WARNING: THROMBOTIC EVENTS and ACUTE AND RECURRENT GALLBLADDER DISEASE See full prescribing information for complete boxed warning. Thrombotic Events Serious thrombotic events have occurred in QFITLIA-treated patients with risk factors including persistent antithrombin (AT) activity less than 15%, QFITLIA 80 mg once monthly dosing, an indwelling venous catheter, and the post-operative setting when bleed management guidelines were not followed. Interrupt QFITLIA in patients with a thrombotic event and manage as clinically indicated. ( 5.1 ) Acute and Recurrent Gallbladder Disease Gallbladder disease has occurred in QFITLIA-treated patients, some requiring cholecystectomy or developing complications (e.g., pancreatitis). Monitor for signs and symptoms of gallbladder disease. Consider interruption or discontinuation of...
What it is approved for
From the label in effect Sep 16, 2025.
QFITLIA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors. QFITLIA is an antithrombin-directed small interfering ribonucleic acid indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors. ( 1 )
Mechanism: QFITLIA is a double-stranded siRNA that causes degradation of AT messenger RNA (mRNA) through RNA interference, reducing plasma AT levels.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 28, 2025 Original approval · Type 1 - New Molecular Entity NovelOrphanMedication GuideLabelLetter
2 products under this application
- QFITLIA · FITUSIRAN SODIUM EQ 20MG BASE/0.2ML (EQ 20MG BASE/0.2ML) · SOLUTION, SUBCUTANEOUS · Prescription
- QFITLIA · FITUSIRAN SODIUM EQ 50MG BASE/0.5ML (EQ 50MG BASE/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fitusiran" as an intervention, any sponsor and status, largest first.
- Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03754790 · 281 participants · Start Jan 9, 2019 · Primary completion Sep 14, 2026
Drug: Fitusiran · For: Hemophilia
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 79 sites in all
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without InhibitorsPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03417245 · 120 participants · Start Mar 1, 2018 · Primary completion Jan 26, 2021
Drug: fitusiran; factor concentrates · For: Hemophilia A; Hemophilia B
Sites: Little Rock, Arkansas; Gainesville, Florida; Tampa, Florida · 64 sites in all
- A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe HemophiliaPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05662319 · 91 participants · Start Feb 1, 2023 · Primary completion Mar 25, 2027
Drug: Fitusiran; Clotting factor concentrates (CFC) or bypassing agents (BPA) and 1 more · For: Hemophilia
Sites: Orange, California; Minneapolis, Minnesota; Hackensack, New Jersey · 50 sites in all
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07285460 · 85 participants (planned) · Start Dec 18, 2025 · Primary completion Aug 4, 2029
Drug: Fitusiran; Clotting factor concentrates (CFC) or bypassing agents (BPA) and 1 more · For: Hemophilia
Sites: Los Angeles, California; Orange, California; Torrance, California · 37 sites in all
- A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent ProphylaxisPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03549871 · 80 participants · Start Jul 25, 2018 · Primary completion Jan 20, 2022
Drug: Fitusiran; BPA prophylaxis and 1 more · For: Hemophilia
Sites: Los Angeles, California; Prahran, Australia; Beijing, China · 35 sites in all
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03417102 · 60 participants · Start Feb 14, 2018 · Primary completion Nov 25, 2020
Drug: fitusiran; Bypassing agents · For: Hemophilia A; Hemophilia B
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 58 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02554773 · 34 participants · Start Sep 18, 2015 · Primary completion Mar 21, 2023
Drug: Fitusiran (SAR439774) · For: Hemophilia A; Hemophilia B
Sites: Ann Arbor, Michigan; Pittsburgh, Pennsylvania; Plovdiv, Bulgaria · 12 sites in all
- Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or BPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03974113 · 32 participants · Start Jan 28, 2020 · Primary completion Aug 4, 2026
Drug: Fitusiran · For: Hemophilia
Sites: Los Angeles, California; Hackensack, New Jersey; Cleveland, Ohio · 16 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- haemorrhage17
- arthralgia9
- off label use8
- contusion7
- chest pain5
- haemarthrosis5
- condition aggravated4
- pain4
- pain in extremity4
- compartment syndrome3
- fall3
- hepatic enzyme increased3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 12 |
| 2026 | 43 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial.
Kenet G, Nolan B, Zulfikar B, et al. · Blood 2024 · Clinical Trial, Phase III, Multicenter Study
- Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.
Young G, Kavakli K, Klamroth R, et al. · Blood 2025 · Clinical Trial, Phase III, Multicenter Study
- Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
Srivastava A, Rangarajan S, Kavakli K, et al. · Lancet Haematol 2023 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
Young G, Srivastava A, Kavakli K, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B.
Pipe SW, Lissitchkov T, Georgiev P, et al. · Blood Adv 2025 · Clinical Trial, Phase II, Multicenter Study
- Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.
Pasi KJ, Rangarajan S, Georgiev P, et al. · N Engl J Med 2017 · Clinical Trial, Phase I, Multicenter Study
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.